Validation of a metered dose inhaler electronic monitoring device: implications for asthma clinical trial use

Background The SmartTouch Ventolin monitor (Adherium, Auckland, New Zealand) is an electronic monitor for use with a Ventolin metered dose inhaler, which records the date and time of inhaler actuations. This technology has the potential to allow in-depth analysis of patterns of inhaler use in clinical trial settings. The aim of this study was to determine the accuracy of the SmartTouch Ventolin monitor in recording Ventolin actuations. Methods 20 SmartTouch Ventolin monitors were attached to Ventolin metered dose inhalers. Bench testing was performed over a 10-week period, to reflect the potential time frame between visits in a clinical trial. Inhaler actuations were recorded in a paper diary, which was compared with data uploaded from the monitors. Results 2560 actuations were performed during the 10-week study period. Monitor sensitivity for diary-recorded actuations was 99.9% with a lower 97.5% confidence bound of 99.7%. The positive predictive value for diary-recorded actuations was 100% with a 97.5% lower confidence bound of 99.9%. Conclusions The SmartTouch Ventolin monitor is highly accurate in recording and retaining electronic data. It can be recommended for use in clinical trial settings in which training and quality control systems are incorporated into study protocols to ensure accurate data acquisition.

[1]  C. Rand,et al.  Electronic Monitoring of Medication Adherence: When Is High-Tech Best? , 2002, Journal of Clinical Psychology in Medical Settings.

[2]  C. Rand,et al.  The Reliability and Patient Acceptability of the SmartTrack Device: A New Electronic Monitor and Reminder Device for Metered Dose Inhalers , 2012, The Journal of asthma : official journal of the Association for the Care of Asthma.

[3]  M. Weatherall,et al.  Three-month validation of a turbuhaler electronic monitoring device: implications for asthma clinical trial use , 2015, BMJ Open Respiratory Research.

[4]  L. Hendeles,et al.  Accuracy of three electronic monitors for metered-dose inhalers. , 2002, Chest.

[5]  D. Shaw,et al.  Predictors of severe exacerbations, poor asthma control, and β-agonist overuse for patients with asthma. , 2014, The journal of allergy and clinical immunology. In practice.

[6]  R. Beasley,et al.  Six-month in vitro validation of a metered-dose inhaler electronic monitoring device: implications for asthma clinical trial use. , 2012, Journal of Allergy and Clinical Immunology.

[7]  D. Shaw,et al.  Metrics of salbutamol use as predictors of future adverse outcomes in asthma , 2013, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[8]  Short-acting β-agonist use as a marker of current asthma control. , 2013, The journal of allergy and clinical immunology. In practice.

[9]  M. Weatherall,et al.  Combination budesonide/formoterol inhaler as maintenance and reliever therapy in Māori with asthma , 2014, Respirology.

[10]  D. Shaw,et al.  Use of metered-dose inhaler electronic monitoring in a real-world asthma randomized controlled trial. , 2013, The journal of allergy and clinical immunology. In practice.

[11]  B. Bender Advancing the science of adherence measurement: implications for the clinician. , 2013, The journal of allergy and clinical immunology. In practice.

[12]  D. Shaw,et al.  Efficacy and safety of maintenance and reliever combination budesonide-formoterol inhaler in patients with asthma at risk of severe exacerbations: a randomised controlled trial. , 2013, The Lancet. Respiratory medicine.